On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel
Similar Posts
CSL Behring – 716297 – 09/09/2025
Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)FDA Holds Meeting with States on Importation of Lower Cost Drugs
FDA held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs to the American consumer.VITAFER-L Gold 10ml may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use VITAFER-L Gold 10ml, a product promoted for energy and sexual enhancement on various websites, including www.amazon.com.Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
Prescription drugs should only be purchased from wholesale drug distributors licensed in the United States. Verify licensing through FDA database links.HealBerry – 09/09/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetRhino 11 Gummy may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Rhino 11 Gummy, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.